Immune responses and predictors of SARS-CoV-2 infection following a fourth dose of mRNA or protein-based COVID-19 vaccines
This study of adults receiving a fourth COVID-19 dose found that while immune responses following subsequent SARS-CoV-2 infection were similar regardless of whether they received an mRNA (Moderna) or protein-based (Novavax) vaccine, the mRNA booster appeared to delay infection longer than the protein-based option, and higher pre-infection antibody levels were associated with reduced infection risk.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
The human immune system is a sophisticated defense network that learns to recognize and fight off invaders like viruses. When a person receives a vaccine, their body is shown a harmless piece of the virus, training its soldiers to build a specific shield, usually in the form of antibodies, that can block the real threat if it ever arrives. Over time, however, this shield can fade, and the virus itself can change its appearance, making the old shield less effective. This is why health experts sometimes recommend booster shots to refresh the body's defenses. A critical question for public health is whether the type of vaccine used matters for how long this protection lasts, and whether the level of antibodies in the blood can predict if a person will get sick again. Understanding these details helps determine when people need another dose and which vaccine platform offers the best long-term safety.
Researchers in Australia set out to answer these questions by studying adults who had already received three doses of a coronavirus vaccine. They recruited nearly five hundred people and divided them into three groups. Two groups received a fourth dose: one group got a vaccine made from genetic instructions, known as an mRNA vaccine, while the other received a vaccine made from actual protein pieces. The third group did not receive a fourth dose at all, serving as a comparison. The study followed these participants for a full year, tracking who became infected with the virus and measuring the levels of their immune defenses at various points. The goal was to see if the type of fourth dose changed how the body reacted to a new infection and to identify if specific immune markers could predict who would stay healthy.
The results showed that once a person got infected, their immune system responded in much the same way, regardless of which vaccine they had received or if they had skipped the fourth dose. Whether the participant had the genetic-based vaccine, the protein-based vaccine, or no new shot at all, the surge in antibodies and other immune signals after infection looked very similar. This suggests that the body's ability to fight off a fresh infection is robust and not heavily dependent on the specific platform of the last booster. However, the study did find a difference in how long it took for people to get infected in the first place. Those who received the mRNA vaccine stayed infection-free for a longer period compared to those who received the protein vaccine. Specifically, the time until ten percent of the participants in the mRNA group became infected was about 191 days, whereas for the protein group, that same milestone was reached at 137 days. This indicates that the mRNA booster may offer a slightly longer window of protection before the virus breaks through.
When the researchers looked at the numbers to see what predicted who would get sick, they found that higher levels of antibodies in the blood were linked to a lower chance of infection, but only after the first six months had passed. In the first half of the year, the amount of antibodies did not seem to make a difference in who got infected. But between six and twelve months, people with higher levels of antibodies against the virus were significantly less likely to catch it. The study also measured a type of immune cell signal, but this did not help predict who would get sick. The findings suggest that while the immediate protection from a booster fades, having a strong antibody level later on can still provide a meaningful shield. The researchers noted that their study had some limitations, such as relying on participants to report their own infections, which means the exact timing of every case might not be perfect. Nevertheless, the data provides a clearer picture of how different boosters work over time and highlights that antibody levels could be a useful tool for deciding when to give the next dose.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.